{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "VIR",
  "name": "Vir Biotechnology, Inc.",
  "url": "https://frontierpicks.com/dossiers/VIR/",
  "json_url": "https://frontierpicks.com/dossiers/VIR.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Q2 (2026-08-05) printed $238.9M revenue and $0.47 diluted EPS on Astellas upfront recognition — an accounting swing, and the tape read it as one: $9.24 on 2026-08-14, still under the $10.36 Astellas equity strike, with Morgan Stanley and Leerink both cutting targets the next day. Nothing hard is dated until ECLIPSE 1 topline in Q4 2026.",
  "invalidation_trigger": "A weekly close below $8.60 voids the June reclaim structure, losing both the 2026-06-17 swing low at $8.86 and the mid-July 50-DMA shelf near $8.71. Secondary breaks: ECLIPSE 1 topline restated past Q4 2026, or VIR-5818 Phase 1 data guided out of H2 2026 at the Q3 print.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "binary-catalyst-biotech",
    "oncology-immunology",
    "precision-biotech-therapeutics",
    "rare-disease-gene-therapy"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Q2 2026 profitability is collaboration-revenue recognition ($240M Astellas upfront), not product revenue — quarterly EPS from this print is not a run-rate.",
    "Astellas took $75M of equity struck at $10.36/share at the 2026-04-15 close; that level sits above spot and is a visible overhead reference.",
    "Astellas funds 60% of global development on the partnered PSMA program, with a US 50/50 profit split and tiered double-digit ex-US royalties.",
    "There is no FDA-approved therapy for chronic hepatitis delta in the US; the ECLIPSE program is being run to change that.",
    "Short-interest trackers diverge materially on VIR share counts between the June 30 and July 15 2026 settlements — read direction, not absolute level."
  ],
  "body_markdown": "## Current Thesis\nThe July frame carried: a funded platform sitting in a catalyst vacuum, waiting on ECLIPSE 1. What changed since is the Q2 print, and it changed less than the headline suggests. On 2026-08-05 Vir reported Q2 revenue of $238.9M and net income of $80.1M ($0.47 diluted, $0.48 basic) against a $111.0M net loss in Q2 2025 — the swing driven by recognition of the $240M Astellas upfront, not by a commercial franchise. Cash, equivalents and investments closed the quarter at approximately $1.01B, up $198.5M sequentially, with runway guided into the second half of 2028. The tape's response is the measurable part: the 2026-08-14 close of $9.24 sits 16.7% below the $11.09 52-week high and below the $10.36 per-share strike at which Astellas took $75M of equity on 2026-04-15. Morgan Stanley cut its target to $25 from $27 and Leerink to $19 from $21, both on 2026-08-06 — the day after a revenue and EPS beat. A beat that produces target cuts and no re-rating says the print was understood as an accounting event.\n\nUnderneath, spend is accelerating into the Phase 3 window: R&D was $135.3M in Q2 versus $97.5M a year earlier (+38.8%), SG&A $30.2M versus $22.3M. The guidance grid is unchanged — ECLIPSE 1 topline Q4 2026, ECLIPSE 2 and 3 Q1 2027, updated VIR-5818 Phase 1 dose-escalation data in H2 2026 (no date attached), VIR-5500 pivotal Phase 3 starts in 2027. Nothing resolves inside 30 days.\n\n**The narrative is maturing.** The narrative is well known and structurally intact — 3-month return is +5.1% and RSI(14) is 60.2, so the name is working, not breaking. But the two events that created new attention are both behind it: the Astellas close on 2026-04-15 and the 2026-08-05 print. Coverage since has been earnings wires and sell-side maintenance rather than fresh headlines, and the two target revisions on 2026-08-06 moved down. That is moderating flow into a known story, which is the definition the site uses for maturing rather than accelerating.\n\n## Bull Case\n- **Q2 2026 (2026-08-05): $1.01B cash, equivalents and investments at 2026-06-30**, up $198.5M in the quarter, with company runway guidance into H2 2028. That funds ECLIPSE 1 (Q4 2026), ECLIPSE 2/3 (Q1 2027) and the 2027 VIR-5500 pivotal starts without a financing window inside the catalyst path.\n- **Astellas terms, closed 2026-04-15**: up to ~$1.7B; $335M upfront and near-term ($240M cash, $75M equity struck at $10.36/share, $20M near-term milestone); US 50/50 profit split, tiered double-digit ex-US royalties, Astellas funding 60% of global development. Spot at $9.24 is below the price a global pharma paid in cash four months ago.\n- **VIR-5500 Phase 1, ASCO GU 2026-02-26 (Abstract #17)**: n=58 post-taxane mCRPC, no dose-limiting toxicities, Grade ≥3 treatment-related AEs 12% (7/58), CRS confined to Grade 1–2. At ≥3,000 µg/kg Q3W: 82% PSA50 (14/17), 53% PSA90 (9/17), 45% RECIST ORR (5/11). Dose-expansion cohorts in metastatic prostate cancer have been initiated per the Q2 update.\n- **SOLSTICE Phase 2 Week 96 (EASL, 2026-05-27 to 05-30)**: 88% (28/32) of participants on combination therapy achieved undetectable HDV RNA. There is no FDA-approved therapy for chronic hepatitis delta in the US, which is the commercial premise ECLIPSE 1 is being run to convert.\n- **Sell-side sits far above tape**: 9 analysts, average target $21.43, high $30, low $16 as of August 2026, with 10 Buy / 0 Hold / 0 Sell on the ratings tally. The gap has persisted, unclosed, for months.\n\n## Bear Case\n- **The beat was non-recurring.** $238.9M of Q2 revenue is Astellas collaboration recognition. There is no product franchise generating it, so Q3 revenue and the return to a loss line are the default expectation, and the $0.47 quarterly EPS is not a run-rate.\n- **Targets moved down on the beat.** Morgan Stanley $27→$25 and Leerink $21→$19, both 2026-08-06. When two houses trim into a revenue and EPS beat, the model that matters is the pipeline model, not the P&L.\n- **Burn is accelerating ahead of the readouts**: R&D $135.3M in Q2 versus $97.5M in Q2 2025; SG&A $30.2M versus $22.3M. Runway guidance is unchanged into H2 2028, but 2027 pivotal Phase 3 starts sit inside that window and the cost curve is rising before the first Phase 3 topline arrives.\n- **The catalyst vacuum is still the dominant fact.** VIR-5818 updated Phase 1 data is guided to H2 2026 with no date. ECLIPSE 1 is Q4 2026. Nothing dated lands before roughly the Q3 print. A name whose next binary is a quarter away trades on flow, and flow is what has been absent since 2026-06-26.\n- **$10.36 overhead.** The Astellas equity strike is a visible reference level above spot that the June impulse (high $10.03 on 2026-06-26) failed to reach.\n- **Short base has not left.** Third-party tabulations show short interest rising again at the 2026-07-15 settlement, reported at 12.7% of float with days-to-cover near 8.7. Trackers disagree materially on the absolute share count versus the 19.19M / 11.72% figure carried at the 2026-06-30 settlement, so read the direction, not the level.\n\n## Setup & Price Structure\nThe 2026-08-14 close of $9.24 is -16.7% from the $11.09 52-week high and roughly flat against the $9.43 close of 2026-07-17, but the 3-month return has flipped from -12.3% in mid-July to +5.1% now, so the drawdown that defined the July note has been absorbed rather than extended. RSI(14) at 60.2 is mid-range: no stretch above trend, no oversold washout to buy against.\n\nReference structure from the June–July sequence: the June 26 high at $10.03 on roughly 7.5M shares, the June 17 swing low at $8.86, the 50-DMA near $8.71 and the 200-DMA near $7.69 as measured in mid-July. Against those, $9.24 keeps the multi-quarter uptrend intact and keeps the name inside the same $8.86–$10.03 range it has occupied since mid-June. The unresolved question is the $10.03–$10.36 band; it has now been rejected once, and reclaiming it on volume well above the ~1.7–1.8M share average is the observable that would say the momentum leg has restarted.\n\nCrowding and positioning observables, stated as observables: short interest reported higher at the 2026-07-15 settlement than at 2026-06-30 (12.7% of float, ~8.7 days to cover, per third-party tabulation with tracker divergence noted above); no earnings date inside 30 days, Q2 having printed 2026-08-05; two price-target reductions on 2026-08-06 against zero increases found in the same window; a strategic holder sitting on equity struck at $10.36, above spot. No retail-forum coverage clustering surfaced in the sampled coverage — the flow here is institutional and sell-side, which is consistent with the maturing label rather than a late-cycle retail bid.\n\n## Catalyst Calendar (next 30 days)\n- **No hard dated clinical or corporate event between 2026-08-15 and 2026-09-14.** This is the material fact for anyone considering the name at $9.24 today.\n- **~2026-11-04 (est.)** — Q3 2026 results. First read on whether R&D above $135M/quarter compresses the H2 2028 runway guide, and the venue where VIR-5818 timing gets restated or slipped.\n- **H2 2026 (undated, company guide)** — updated VIR-5818 Phase 1 dose-escalation data, monotherapy and in combination with pembrolizumab. Could land inside or well outside a 30-day window; management has attached no date.\n- **Q4 2026 (company guide)** — ECLIPSE 1 Phase 3 topline in chronic hepatitis delta. The first pivotal readout and the actual binary.\n- **Q1 2027 (company guide)** — ECLIPSE 2 and ECLIPSE 3 topline, which together with ECLIPSE 1 determine whether the HDV package supports a global regulatory filing.\n\n## What Would Change Our Mind\nThe structure that matters is the June range floor, not the trend line. Losing $8.86 (the 2026-06-17 swing low) and the mid-July 50-DMA shelf near $8.71 in the same move would void the entire June reclaim attempt and leave the 200-DMA region near $7.69 as the next reference — with no dated catalyst between here and Q4 2026 to arrest it. Concretely: **a weekly close below $8.60** breaks the thesis on price.\n\nThree non-price conditions would do the same work. First, ECLIPSE 1 topline being restated as anything later than Q4 2026 at the Q3 print — the entire two-quarter wait is priced against that date holding. Second, VIR-5818 Phase 1 data being guided out of H2 2026, which would remove the only potential 2026 event other than ECLIPSE 1. Third, any new dose-limiting toxicity or Grade ≥3 CRS emerging from the VIR-5500 metastatic prostate dose-expansion cohorts, since the differentiated safety profile — no DLTs, 12% Grade ≥3 TRAEs, CRS Grade 1–2 only at n=58 — is the specific claim the Astellas economics were written against.\n\nOn the other side, the condition that would upgrade the read is narrow and observable: a reclaim of the $10.03–$10.36 band on volume materially above the ~1.7–1.8M share average, or management attaching a calendar date to either VIR-5818 or ECLIPSE 1. Absent one of those, this is a low-conviction setup at $9.24 — early rather than cheap, and the $21.43 average target is not a floor.\n\n## Correlation Notes\n- **Janux Therapeutics (JANX)** remains the read-across for masked T-cell-engager differentiation. A clean JANX dataset landing before VIR-5500 expansion data would compress the scarcity premium underwriting the Astellas structure; a JANX safety problem would widen it. This is the highest-information external event for the oncology half of the story.\n- **Astellas (4503.T)** is now a P&L counterparty, not just a licensor: 60% of global development cost and a US 50/50 profit split mean Astellas capital-allocation commentary on the PSMA program is a direct input.\n- **Gilead (GILD)** sets the HDV comparator context through bulevirtide; ECLIPSE 1 will be read against that benchmark rather than in isolation.\n- **XBI / small-cap biotech beta** dominates day-to-day movement in a catalyst vacuum. With no company-specific event dated before Q4 2026, index-level risk appetite and rate expectations explain more of the next 30 days of price action than anything in the pipeline.",
  "first_seen": "2026-04-19",
  "last_analyzed": "2026-08-15T12:31:38+00:00",
  "last_synthesized": "2026-08-15",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}